In vitro susceptibility of Bartonella species to 17 antimicrobial compounds: Comparison of Etest and agar dilution

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 784-788

  Dörbecker, Christina ^a,c   Sander, Anna ^a   Oberle, Karin ^a   Schülin Casonato, Tanja ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Aminoglycosides; Fluoroquinolones; Macrolides; MICs; Telithromycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; NETILMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; STREPTOMYCIN; STREPTOMYCIN GRUNENTHAL; TELITHROMYCIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BARTONELLA; BARTONELLA ALSATICA; BARTONELLA DOSHIAE; BARTONELLA ELIZABETHAE; BARTONELLA GRAHAMII; BARTONELLA HENSELAE; BARTONELLA QUINTANA; BARTONELLA SCHOENBUCHII; BARTONELLA TRIBOCORUM; BARTONELLA VINSONII; BARTONELLACEAE; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DRUG EFFICACY; DRUG POTENCY; HUMIDITY; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RELIABILITY; STRAIN DIFFERENCE;

AGAR; ANIMALS; ANTI-BACTERIAL AGENTS; BARTONELLA; CATS; CULTURE MEDIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 33748694304     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl341     Document Type: Article

References (34)

1. Maillard R, Riegel P, Barrat F et al. Bartonella chomelii sp. nov., isolated from French domestic cattle (Bos taurus). Int J Syst Evol Microbiol 2004; 54: 215-20.
2. Gundi VA, Davoust B, Khamis A et al. Isolation of Bartonella rattimassiliensis sp. nov. and Bartonella phoceensis sp. nov. from European Rattus norvegicus. J Clin Microbiol 2004; 42: 3816-8.
3. Sander A. Bartonellosis. In: Cimolai N, ed. Laboratory Diagnosis of Bacterial Infections. New York: Marcel Decker, 2001; 653-86.
4. Dehio C, Sander A. Bartonella as emerging pathogens. Trends Microbiol 1999; 7: 226-8.
5. La Scola B, Raoult D. Culture of Bartonella quintana and Bartonella henselae from human samples: A 5-year experience (1993-1998). J Clin Microbiol 1999; 37: 1899-905.
6. Rolain JM, Brouqui P, Koehler JE et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48: 1921-33.
7. Margileth AM. Antibiotic therapy for cat-scratch disease: Clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11: 474-8.
8. Sander A, Bühler C, Pelz K et al. Detection and identification of two Bartonella henselae variants in domestic cats in Germany. J Clin Microbiol 1997; 35: 584-7.
9. Sander A, Ruess M, Bereswill S et al. Comparison of different DNA fingerprint techniques for molecular typing of Bartonella henselae isolates. J Clin Microbiol 1998; 36: 2973-81.
10. Schmidt HU, Kaliebe T, Poppinger J et al. Isolation of Bartonella quintana from an HIV-positive patient with bacillary angiomatosis. Eur J Clin Microbiol Infect Dis 1996; 15: 736-41.
11. Dehio C, Lanz C, Pohl R et al. Bartonella schoenbuchii sp. nov., isolated from the blood of wild roe deer. Int J Syst Evol Microbiol 2001; 51: 1557-65.
12. Rolain JM, Maurin M, Bryskier A et al. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella bumetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob Agents Chemother 2000; 44: 1391-3.
13. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-6.
14. Schülin T, Wennersten CB, Ferraro MJ et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520-3.
15. Maurin M, Mersali NF, Raoult D. Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob Agents Chemother 2000; 44: 3428-31.
16. Rolain JM, Maurin M, Mallet MN et al. Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes. Antimicrob Agents Chemother 2003; 47: 614-9.
17. Myers WF, Grossman DM, Wisseman CL Jr. Antibiotic susceptibility patterns in Rochalimaea quintana, the agent of trench fever. Antimicrob Agents Chemother 1984; 25: 690-3.
18. Maurin M, Raoult D. Antimicrobial susceptibility of Rochalimaea quintana, Rochalimaea vinsonii, and the newly recognized Rochalimaea henselae. J Antimicrob Chemother 1993; 32: 587-94.
19. Wolfson C, Branley J, Gottlieb T. The Etest for antimicrobial susceptibility testing of Bartonella henselae. J Antimicrob Chemother 1996; 38: 963-8.
20. Sobraques M, Maurin M, Birtles RJ et al. In vitro susceptibilities of four Bartonella bacilliformis strains to 30 antibiotic compounds. Antimicrob Agents Chemother 1999; 43: 2090-2.
21. Maurin M, Gasquet S, Ducco C et al. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolated Antimicrob Agents Chemother 1995; 39: 2387-91.
22. Ives TJ, Manzewitsch P, Regnery RL et al. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother 1997; 41: 578-82.
23. Pendle S, Ginn A, Iredell J. Antimicrobial susceptibility of Bartonella henselae using Etest methodology. J Antimicrob Chemother 2006; 57: 761-3.
24. Krause R, Wenisch C, Fladerer P et al. Osteomyelitis of the hip joint associated with systemic cat-scratch disease in an adult. Eur J Clin Microbiol Infect Dis 2000; 19: 781-3.
25. Gazineo JL, Trope BM, Maceira JP et al. Bacillary angiomatosis: description of 13 cases reported in five reference centers for AIDS treatment in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2001; 43: 1-6.
26. Bass JW, Freitas BC, Freitas AD et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17: 447-52.
27. Rolain JM, Maurin M, Raoult D. Bactericidal effect of antibiotics on Bartonella and Brucella spp.: Clinical implications. J Antimicrob Chemother 2000; 46: 811-4.
28. Reynolds AV, Hamilton-Miller JM, Brumfitt W. Diminished effect of gentamicin under anaerobic or hypercapnic conditions. Lancet 1976; 1: 447-9.
29. Traub WH, Leonhard B. Antibiotic susceptibility tests with fastidious and nonfastidious bacterial reference strains: Effects of aerobic versus hypercapnic incubation. Chemotherapy 1995; 41: 18-33.
30. Schülein R, Seubert A, Gille C et al. Invasion and persistent intracellular colonization of erythrocytes. A unique parasitic strategy of the emerging pathogen Bartonella. J Exp Med 2001; 193: 1077-86.
31. Musso D, Drancourt M, Raoult D. Lack of bactericidal effect of antibiotics except aminoglycosides on Bartonella (Rochalimaea) henselae. J Antimicrob Chemother 1995; 36: 101-8.
32. Raoult D, Fournier P-E, Vandenesch F et al. Outcome and treatment of Bartonella Endocarditis. Arch Intern Med 2003; 163: 226-30.
33. Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. Antimicrob Agents Chemother 2003; 47: 2204-7.
34. Foucault C, Barrau K, Brouqui P et al. Bartonella quintana bacteremia among homeless people. Clin Infect Dis 2002; 35: 684-9.